GlassScriptPhysician profile
Whitney Pugh
NPI 1003444183
$866.82
in general payments reported to CMS, 2019-2025
22 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $195 · 2023: $134 · 2024: $289 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $151.62 | 2024-2025 | Azstarys |
| Abbvie INC. | $72.92 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $69.74 | 2024-2025 | Myfembree, Gemtesa |
| Aspira Women'S Health INC | $65.64 | 2024 | Ova1 |
| Exeltis, USA INC. | $65.26 | 2023-2025 | Slynd |
| Amgen INC. | $40.56 | 2022-2025 | Prolia, Evenity |
| Pfizer INC. | $39.53 | 2022-2023 | |
| Astellas Pharma US INC | $37.19 | 2024 | Veozah |
| Hologic Sales and Service, LLC | $34.53 | 2023-2025 | Aptima |
| Novo Nordisk INC | $33.24 | 2023 | Wegovy |
| Medtronic, INC. | $32.60 | 2022-2023 | Interstim |
| Ultragenyx Pharmaceutical INC. | $30.96 | 2022 | |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Coopersurgical, INC. | $21.71 | 2023 | Paragard T 380a |
| Organon LLC | $21.66 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $20.20 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $18.95 | 2022 | |
| Glaxosmithkline, LLC. | $18.92 | 2024 | Bexsero |
| Biomarin Pharmaceutical INC. | $17.90 | 2025 | Voxzogo 1.2mg |
| Shield Therapeutics INC | $17.36 | 2023 | Accrufer |
| Supernus Pharmaceuticals, INC. | $16.14 | 2025 | Qelbree |
| Solventum Corporation | $13.54 | 2024 | Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Pugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.